Big biotech, Deals

Morphosys acquires Lanthio Pharma

Posted on 07 May 2015

Tags: ,

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.

The transaction brings Lanthio Pharma's lead compound LP2, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases to MorphoSys's growing proprietary portfolio.

 

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

LP2, which will be re-named MOR107, has demonstrated potent angiotensin II type 2 (AT2) receptor-dependent activity in vivo, and is planned to enter clinical trials in 2016.

LP2 is the most advanced of four lanthipeptides in Lanthio Pharma's portfolio.

Prior to the acquisition, MorphoSys held 19.98% of Lanthio Pharma.

MorphoSys will pay EUR 20 million to acquire the outstanding share capital of Lanthio Pharma from the other investors, among them INKEF Capital, BioGeneration Ventures and Hanzepoort.

As part of its Innovation Capital initiative, MorphoSys had made its initial equity investment in November 2012 as part of Lanthio Pharma's Series A financing round.

Print Friendly, PDF & Email

Leave a Reply